Skip to contentS
Supernus Pharmaceuticals, Inc.
S
SUPNSupernus Pharmaceuticals, Inc. Q3 2016 · 10-Q
Revenue$56.81M$56.81M+44.3% vs Q3 2015 Net Income$61.83M$61.83M+1,478.8% vs Q3 2015 EPS Diluted$1.18$1.18+1,375.0% vs Q3 2015 Operating Income$19,839,000+290.1% Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Supernus Pharmaceuticals, Inc. · CIK 1356576 · Engraved from SEC EDGAR
derived
Free Cash Flowderived$27,840,000N/M Margins · derivedOperating margin34.9%+22.0 pt vs Q3 2015
Net margin108.8%+98.9 pt vs Q3 2015
ended Sep 30, 2016 · filed Jan 20, 2017 · 112 d after period end